Young Sook Choi, Kwang Soo Lee, M.D., Sang Ho Kim, M.D. Background: Complementary receptors have been suggested to play causative roles in the neuroinflammatory process of Alzheimer's disease (AD). The genetic expressions of the C3a receptor (C3aR), C5a receptor (C5aR) and the protein expressions of the C3aR and C5aR were examined in the human neuroblastoma cell line, SK-N-SH, after the administration of amyloid peptide (A1-42). Methods: SK-N-SH cells were incubated overnight with a single dose of 20 M of aggregated A (A1-42). An inhibition study was done with actinomycin D (ActD, 2.5 M) or with the administration of cycloheximide (CHX, 2.5 M) to the cell suspension. Messenger RNA expressions of C3aR and C5aR were detected by RT-PCR. The intensity of bands from 6% polyacrylamide electrophoretic gel was analyzed by a bioimage analyzer. The protein production of C3aR and C5aR in the A-treated cells was also measured by flow cytometry. NFB activation after treatment of A in the cells was detected by an electrophoretic mobility-shift assay. Results: A1-42 increased the expression of C3aR and C5aR. ActD inhibited the expression of both anaphylatoxin receptors but CHX only suppressed C5aR mrna expression. Activated NFB was demonstrated in the A-stimulated cells. Conclusions: C3aR and C5aR were constitutively expressed in the human neuroblastoma SK-N-SH cell. Expression of these anaphylatoxin receptors was upregulated after A1-42 stimulation, which as a result, may contribute to the complement-mediated neuroinflammation of AD. J Korean Neurol Assoc 22(1):52 58, 2004 Key Words: Complement C3a receptors, Complement C5a receptors, Alzheimer's disease, Actinomycin, Amyloid beta-protein 서론
대상과방법 22 권 1 호대한신경과학회지
결과 Figure 1. Messenger RNA expression of anaphylatoxin receptor genes. (A) Representative photograph shows RT-PCR products of C3a receptor and C5a receptor mrnas. Neuroblastoma SK-N-SH cells are stimulated overnight by A 1-42 (20 M). The cdna has been obtained from a total RNA extract of cells. Electrophoretic separation is performed on a 6% polyacrylamide gel. Note the extraordinary increased mrna expression of C5a receptor after Astimulation. (B) Bar graphs show relative levels of anaphylatoxin receptor mrnas in cell extracts. Relative optical densities represent readings of gel band intensities as determined on a Fuji (BAS-2500) bioimage analyzer with quantitative analysis and use of Tina software 2.10 (Fuji). The mean±s.e. of 2~4 independent experiments are shown. * P<0.05 vs control(tnf-/a -). Student's t-test.
Figure 2. Flow cytometry analysis of the expression of anaphylatoxin receptors by SK-N-SH cells. (A) Dot plot of the C3aR and the C5aR from A 1-42 (20 M) stimulated cells. Samples are prepared as described in Materials and Methods. The mean±s.e. of 3 independent experiments are shown. (B) Histograms of the C3aR and C5aR control; 20 M A 1-42. Figure 3. Effect of actinomycin D (2.5 M) on the mrna expression of anaphylatoxin receptors from A 1-42 stimulated SK-N-SH cells. (A) The expression of mrnas for C3a receptor and C5a receptor is suppressed, respectively. (B) Optical density is measured with bioimage analyzer as in figure 1. The mean±s.e. of 2~4 independent experiments are shown. * P<0.05 vs A +/ActD-. Student's t-test. ActD; actinomycin D. 22 권 1 호대한신경과학회지
Figure 4. Effect of cycloheximide (2.5 M) on the mrna expression of anaphylatoxin receptor from A 1-42 stimulated SK-N-SH cells. (A) The expression of mrna for C5a receptor is obviously suppressed. (B) Optical density is measured with a bioimage analyzer as in figure 1. The mean±s.e. of 2~4 independent experiments are shown. * P<0.05 vs A +/CHX-. Student's t-test. CHX; cycloheximide. Figure 5. Effect of A 1-42 on NF B activity in SK-N-SH cells. (A) NF B activity is elevated in A 1-42 stimulated cells. (B) The nuclear protein-nf B complex (indicated by the arrow) is verified by suppression of the binding activity with an excess of cold NF B but not with cold AP-1 oligonucleotide. The supershift of the complex is seen by either anti-p50 and anti-p65 antibodies. 고찰
1. Selkoe DJ. Physiological production of the -amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 1993;16:403-409. 2. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-159. 3. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 1999;57: 301-323. 4. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-1239. 5. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421. 6. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000;49:171-186. 7. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid protein toxicity. Cell 1994;77:817-827. 8. Golde TE. Inflammation takes on Alzheimer disease. Nat Med 2002;8:936-938. 9. Hu J, Akama KT, Krafft GA, Chromy BA, van Eldik LJ. Amyloid- peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998;785:195-206. 10. Han SY, Choi YS, Lee KS, Kim SH. Induction of various pro-inflammatory mediators and their receptors in the human astrocytoma cell line stimulated by - amyloid protein administration. J Korean Neurol Assoc 2002;20:515-524. 11. Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mrnas for complement proteins of the classical pathway in Alzheimer brain. Brain Res 1997;769:391-395. 12. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJM, Rozemuller JM, Veerhuis R, et al. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002;40:232-239. 13. Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today 1996;17: 461-466. 22 권 1 호대한신경과학회지
14. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 1982;57:239-242. 15. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989;107:341-346. 16. Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 1997;769:385-390. 17. Mukherjee P, Pasinetti GM. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol 2000;105:124-130. 18. Fischer B, Schmoll H, Riederer P, Bauer J, Platt D, Popa- Wagner A. Complement C1q and C3 mrna expression in the frontal cortex of Alzheimer's patients. J Mol Med 1995; 73:465-471. 19. Paradisis PM, Campbell IL, Barnum SR. Elevated complement C5a receptor expression on neurons and glia in astrocyte-targeted interleukin-3 transgenic mice. Glia 1998; 24:338-345. 20. Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease peptide. J Exp Med 1998;188:431-438. 21. Choi YS, Lee KS, Kim SH. Expression of Complement Regulator Genes in A 1-42 Stimulated Human Neuroblastoma Cell. J Korean Neurol Assoc 2003;21:513-520. 22. Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 1999;26:201-211. 23. Gasque P, Singhrao SK, Neal JW, Wanf P, Sayah S, Fontaine M, et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998;160:3543-3554. 24. Farkas I, Baranyi L, Takahashi M, Fukuda A, Liposits Z, Yamamoto T, et al. A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J Physiol 1998;507:679-687. 25. O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166: 4154-4162. 26. Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J Neuroimmunol 1995;61:71-78. 27. Osaka H, Mulkherjee, P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999;73: 303-311. 28. Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci 1999;22:397-402. 29. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF- B is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997;94:2642-2647. 30. Gamalei IA, Kirpichnikova KM, Ishchenko AM, Zhakhov AV, Kliubin IV. Activation of astrocytes by anaphylatoxins of the C system. Tsitologiia 1998;40:768-772. 31. Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Goetze O et al. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 1995;155:4882-4889. 32. Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GM. Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience 1999;88:1073-1082. 33. Sayah S, Ischenko AM, Zhakhov A, Bonnard AS, Fontaine M. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mrna expression. J Neurochem 1999;72:2426-2436.